Synergistic action of JAK 1/2, glutaminolysis, and glycolysis inhibitors in JAK2-mutated MPN. The figure highlights that combined treatment of JAK2-V617F–mutated MPN with inhibitors of metabolic dependencies (ie, CB-839 and/or 3PO) together with JAK 1/2 inhibitors (ie, ruxolitinib) synergistically acts in reducing malignant clone size, BM fibrosis, inflammation, and splenomegaly.